Lower expression of PDZRN3 induces endometrial carcinoma progression via the activation of canonical Wnt signaling

Li,Qiuhong; Zhong,Jie; Yang,Shangjie; Liang,Yanping

doi:10.3892/ol.2022.13218

Lower expression of PDZRN3 induces endometrial carcinoma progression via the activation of canonical Wnt signaling

Authors:
- Qiuhong Li
- Jie Zhong
- Shangjie Yang
- Yanping Liang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Shanghai Yangpu District Shidong Hospital, Shanghai 2000438, P.R. China, Department of Obstetrics and Gynecology, Yangpu Hospital Affiliated to Tongji University, Shanghai 200090, P.R. China
Published online on: January 27, 2022 https://doi.org/10.3892/ol.2022.13218
Article Number: 98

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endometrial carcinoma (EC) exhibits an extremely malignant biological behavior and has a high mortality rate. EC has recently become one of the most lethal cancers in women worldwide. E3 ubiquitin ligases play an important role in the biological function of healthy cells but can also contribute to tumorigenesis and cancer development. PDZ Domain Containing Ring Finger 3 (PDZRN3) is associated with cell differentiation and its structure includes the E3 ubiquitin ligase. However, the effects of PDZRN3 in EC remain unclear. Reverse transcription‑quantitative PCR was used to detect the expression levels of PDZRN3 in EC cells, and the role of PDZRN3 in EC progression was determined using western blotting, MTT, colony formation, Transwell, subcutaneous tumor formation and pulmonary metastasis assays. A multi‑pathway reporter arrays and western blotting were performed to investigate the potential biological mechanisms of PDZRN3 in EC. The present study demonstrated that PDZRN3 served an essential role in metastasis and proliferation of EC. PDZRN3 expression was lower in EC tissues compared with that in normal endometrial tissues. Low expression level of PDZRN3 in EC was correlated with certain clinicopathological features of patients with EC, such as the age of the patients, the tumor grade and the tumor subtype. The invasive and proliferative activities of EC cells with low expression of PDZRN3 were more potent than those of EC cells with high expression of PDZRN3, which was confirmed by in vivo and in vitro experiments. Furthermore, lower expression of PDZRN3 promoted metastasis and proliferation via activation of the canonical Wnt signaling pathway. The present study demonstrated that decreased PDZRN3 expression promoted metastasis and proliferation in EC cells via activation of the canonical Wnt signaling pathway, highlighting a potential biological therapeutic target for the management of EC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Washington CR, Haggerty A, Ronner W, Neff PM and Ko EM: Knowledge of endometrial cancer risk factors in a general gynecologic population. Gynecol Oncol. 158:137–142. 2020. View Article : Google Scholar : PubMed/NCBI
3	Byrne FL, Martin AR, Kosasih M, Caruana BT and Farrell R: The role of hyperglycemia in endometrial cancer pathogenesis. Cancers (Basel). 12:11912020. View Article : Google Scholar : PubMed/NCBI
4	Nagao S: IV. Endometrial Cancer. Gan To Kagaku Ryoho. 47:247–251. 2020.(In Japanese). PubMed/NCBI
5	Lamothe S and Ramia de Cap M: Survival analysis and treatment effects in patients with endometrial cancer and POLE mutations. Cancer. 127:4306–4307. 2021. View Article : Google Scholar : PubMed/NCBI
6	Luna C, Balcacer P, Castillo P, Huang M and Alessandrino F: Endometrial cancer from early to advanced-stage disease: An update for radiologists. Abdom Radiol (NY). 46:5325–5336. 2021. View Article : Google Scholar : PubMed/NCBI
7	Deng L, Meng T, Chen L, Wei W and Wang P: The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 5:112020. View Article : Google Scholar : PubMed/NCBI
8	Pérez-Benavente B, Nasresfahani AF and Farràs R: Ubiquitin-regulated cell proliferation and cancer. Adv Exp Med Biol. 1233:3–28. 2020. View Article : Google Scholar : PubMed/NCBI
9	Faktor J, Pjechová M, Hernychová L and Vojtěšek B: Protein ubiquitination research in oncology. Klin Onkol. 32 (Suppl 3):S56–S64. 2019. View Article : Google Scholar : PubMed/NCBI
10	Fan Q, Wang Q, Cai R, Yuan H and Xu M: The ubiquitin system: orchestrating cellular signals in non-small-cell lung cancer. Cell Mol Biol Lett. 25:12020. View Article : Google Scholar : PubMed/NCBI
11	Jiang Q, Li F, Cheng Z, Kong Y and Chen C: The role of E3 ubiquitin ligase HECTD3 in cancer and beyond. Cell Mol Life Sci. 77:1483–1495. 2020. View Article : Google Scholar : PubMed/NCBI
12	Liu X, Zurlo G and Zhang Q: The roles of Cullin-2 E3 ubiquitin ligase complex in cancer. Adv Exp Med Biol. 1217:173–186. 2020. View Article : Google Scholar : PubMed/NCBI
13	Venuto S and Merla G: E3 ubiquitin ligase TRIM proteins, cell cycle and mitosis. Cells. 8:5102019. View Article : Google Scholar : PubMed/NCBI
14	Wang ZW, Hu X, Ye M, Lin M, Chu M and Shen X: NEDD4 E3 ligase: Functions and mechanism in human cancer. Semin Cancer Biol. 67:92–101. 2020. View Article : Google Scholar : PubMed/NCBI
15	Katoh M and Katoh M: Identification and characterization of PDZRN3 and PDZRN4 genes in silico. Int J Mol Med. 13:607–613. 2004.PubMed/NCBI
16	Ko JA, Kimura Y, Matsuura K, Yamamoto H, Gondo T and Inui M: PDZRN3 (LNX3, SEMCAP3) is required for the differentiation of C2C12 myoblasts into myotubes. J Cell Sci. 119:5106–5113. 2006. View Article : Google Scholar : PubMed/NCBI
17	Marracci S, Vangelisti A, Raffa V, Andreazzoli M and Dente L: pdzrn3 is required for pronephros morphogenesis in Xenopus laevis. Int J Dev Biol. 60:57–63. 2016. View Article : Google Scholar : PubMed/NCBI
18	Marunaka K, Furukawa C, Fujii N, Kimura T, Furuta T, Matsunaga T, Endo S, Hasegawa H, Anzai N, Yamazaki Y, et al: The RING finger- and PDZ domain-containing protein PDZRN3 controls localization of the Mg²⁺ regulator claudin-16 in renal tube epithelial cells. J Biol Chem. 292:13034–13044. 2017. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Sewduth RN, Jaspard-Vinassa B, Peghaire C, Guillabert A, Franzl N, Larrieu-Lahargue F, Moreau C, Fruttiger M, Dufourcq P, Couffinhal T and Duplàa C: The ubiquitin ligase PDZRN3 is required for vascular morphogenesis through Wnt/planar cell polarity signaling. Nat Commun. 5:48322014. View Article : Google Scholar : PubMed/NCBI
21	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
22	Nikolaou S and Machesky LM: The stressful tumour environment drives plasticity of cell migration programmes, contributing to metastasis. J Pathol. 250:612–623. 2020. View Article : Google Scholar : PubMed/NCBI
23	Jamil A and Kasi A: Lung Metastasis. StatPearls (Internet). StatPearls Publishing; Treasure Island, FL: 2021
24	Lu C, Ning G, Si P, Zhang C, Liu W, Ge W, Cui K, Zhang R and Ge S: E3 ubiquitin ligase HECW1 promotes the metastasis of non-small cell lung cancer cells through mediating the ubiquitination of Smad4. Biochem Cell Biol. 99:675–681. 2021. View Article : Google Scholar : PubMed/NCBI
25	Shen J, Yu Z and Li N: The E3 ubiquitin ligase RNF146 promotes colorectal cancer by activating the Wnt/β-catenin pathway via ubiquitination of Axin1. Biochem Biophys Res Commun. 503:991–997. 2018. View Article : Google Scholar : PubMed/NCBI
26	Honda T and Inui M: PDZRN3 regulates differentiation of myoblasts into myotubes through transcriptional and posttranslational control of Id2. J Cell Physiol. 234:2963–2972. 2019. View Article : Google Scholar : PubMed/NCBI
27	Honda T and Inui M: PDZRN3 protects against apoptosis in myoblasts by maintaining cyclin A2 expression. Sci Rep. 10:11402020. View Article : Google Scholar : PubMed/NCBI
28	Sewduth RN, Kovacic H, Jaspard-Vinassa B, Jecko V, Wavasseur T, Fritsch N, Pernot M, Jeaningros S, Roux E, Dufourcq P, et al: PDZRN3 destabilizes endothelial cell-cell junctions through a PKCζ-containing polarity complex to increase vascular permeability. Sci Signal. 10:eaag32092017. View Article : Google Scholar : PubMed/NCBI
29	Chatterjee A, Paul S, Bisht B, Bhattacharya S, Sivasubramaniam S and Paul MK: Advances in targeting the WNT/β-catenin signaling pathway in cancer. Drug Discov Today. Jul 10–2021.(Epub ahead of print).
30	Fatima I, Barman S, Rai R, Thiel KWW and Chandra V: Targeting Wnt signaling in endometrial cancer. Cancers (Basel). 13:23512021. View Article : Google Scholar : PubMed/NCBI